DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application | DiaCarta, Inc.

DiaCarta Demos Liquid Biopsy Use for ColoScape Assay, Plans to Market Expanded Application

by | Oct 27, 2017 | Blog

NEW YORK (GenomeWeb) – MDx firm Diacarta shared new data today on the use of its colorectal cancer mutation assay in analyzing blood samples of patients with early-stage colorectal cancer, positioning the kit as a liquid biopsy tool.

The firm could potentially compete with or enhance other amplification-based systems that are increasingly being explored and adopted into clinical practice.

Researchers shared the data in an abstract at the American Association for Cancer Research’s International Conference on Molecular Targets and Cancer Therapeutics this morning, reporting that their technology successfully detected circulating cancer mutations in 92 percent of cases across a range of cancer stages.


ColoScape is already CE marked as of February this year, but DiaCarta CSO Michael Powell said that the firm has been marketing it mainly for FFPE tissue samples so far.

Elena Peletskaya, DiaCarta’s director of diagnostics, added that the plan is to begin promoting the kits for both tissue and plasma very soon.

“We already have the studies and documentation available, it’s just figuring out the best time to announce it,” she said.

Since the first US Food and Drug Administration approval of a liquid biopsy assay — Roche’s cobas EGFR Mutation Test — last year, diagnostics developers, clinicians, and other stakeholders have begun to discuss what the future holds for various PCR technologies in this new area of clinical testing.

At a recent meeting co-sponsored by the FDA and AACR for example, participants discussed how the field is now grappling with whether the cobas assay should be the default for clinical testing, or if other laboratory-developed tests might be superior.

Current alternatives in the LDT space include assays using Bio-Rad’s droplet digital PCR, which Geoffrey Oxnard and colleagues at Dana Farber said they have embraced over the Roche kit.

Sysmex Inostics’ BEAMing technology has also been paid significant attention in clinical studies, as has Inivata’s next-gen sequencing-based technology.

Powell said that DiaCarta believes that its xenonucleic acid (XNA) method — which suppresses the amplification of normal DNA sequences to allow selective amplification of mutated targets — can offer the field a competitively sensitive alternative to things like ddPCR and BEAMing, but without the need to significantly change either methodology or lab instrumentation.

“We wanted to keep technology as simple as possible to not change the existing infrastructure, so it can work on existing machines or instruments,” he said. “That’s what XNA is. It’s an ingredient not a cake,” he added.

In the validation study presented today, DiaCarta investigators analyzed a total of 324 colorectal cancer samples — both tissue biopsies and plasma — representing a range of cancer stages using ColoScape.

Excluding adenoma cases, the test detected the presence of cancer mutations with 95 percent specificity and 91 percent sensitivity in tissue. In plasma, the assay detected mutations with 92 percent specificity and 86 percent sensitivity, the authors reported.

While lung cancer has emerged as the poster child for the clinical adoption of liquid biopsy, colorectal cancer is also an area of increasing activity, and one where tests are being pushed further toward early detection and monitoring, as opposed to later-stage disease.

Researchers have determined, for example, that blood-based mutation detection can be used to monitor response to therapy, and may even work in early-stage disease to predict which patients are likely to maintain a disease-free status after surgical removal or their tumors alone and which should get added chemotherapy treatment.

DiaCarta is positioning its ColoScape assay in this vein as well. In an announcement highlighting the data at the meeting today, the company said that though it believes ColoScape could be used for screening, the nearer-term applicability is for triage, recurrence, and monitoring.

In the case of triage, the company means that it could be administered to patients who have had a positive fecal hemoglobin test or based on some other clinical suspicion. If the patient then tested positive using ColoScape, there would be additional rationale to move forward to a colonoscopy.

The company also envisions the assay being used to monitor patients following surgery or chemotherapy, similar to what groups have begun to demonstrate using other PCR approaches.

With near-term plans to make the test available to CE-IVD users abroad and research-use-only customers in the US, DiaCarta also said that it plans to seek clinical regulatory approval for the kit in the US and China.

The company is also working on validating several other existing kits for mutations in genes like EGFR, BRAF, and PIK3CA, to be used in blood as well as tissue samples. Peletskaya said that the firm’s KRAS assay is already validated for blood in addition to tissue.

Finally, through its CLIA lab, DiaCarta is already offering its pan-cancer OptiSeq NGS test for blood-based mutation detection, Powell added. The assay targets 2,900 commonly observed hotspots in 65 oncogenes and tumor suppressor genes, and the company uses Qiagen’s Clinical Insight Interpret software suite to classify variants based on guidelines and curate results into a final clinical report.


Lead Source

Confirmation of NGS for False-negative Variants Using XNA Technology

Next-generation sequencing (NGS) is a powerful tool that has seen a fast increase in clinical labs although only a few NGS tests have been approved by the FDA. However, there have been a lot of debate on if variants from NGS sequencing should be confirmed either by Sanger sequencing, the gold standard, or other techniques such as quantitative PCR, or the combination, or other methods.

XNA Molecular Clamps Help Identify False-positive T790M Mutation

Eighty five percent of the lung cancer patients are non-small cell lung cancer (NSCLC) patients. Among this population, patients with exon 19 deletion and L858R mutations respond well to the first (such as erlotinib and gefitinib) and second generation (such as afatinib and dacomitinib) of tyrosine kinase inhibitors (TKIs). However, all the respondents develop resistance after 9 to 14-month period and more than 50% of the resistance cases are due to the single point mutation at exon 20, T790M.

Colorectal Cancer: Early Screening Could Save Your Life

linkedinfacebooktwitterColorectal cancer (CRC), including colon and rectum cancer, is the third most common cancer in the world and the third in the US as well. American Cancer Society (ACS) estimates that there are 97,220 and 43,030 new cases in 2018 for colon and...

Detecting BRAF (V600E) Mutation in FFPE or Blood Samples

linkedin facebook twitter When mutated, oncogenes can convert normal cells to cancer cells. BRAF is one of the oncogenes that controls transduction of chemical signal from outside the cells to nucleus. As a member of the RAS/MAPK pathway, the BRAF gene product, the...

DiaCarta: Dedicated to the Science of Impact

linkedinfacebooktwitterMolecular Diagnostics has evolved over the years and the numerous benefits it has to offer has earned people’s attention irrespective of the expensive procedures it included. Quicker turnaround times, improved sensitivities, increased accuracy...

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!